The impact of Clonidine, a pharmacological treatment for attention deficit hyperactivity disorder (ADHD), on behavioural and brain imaging measures of attention, inhibition and error processing.
A randomised, placebo controlled trial of the effects of Clonidine (200 mcg) on cognitive control and error processing measures (recorded with electroencephalogram (EEG) during behavioural tasks) in a sample of 26 healthy adult males.
Professor Mark Bellgrove
26 participants
Feb 3, 2015
Interventional
Conditions
Summary
This study assesses the impact of Clonidine a commonly prescribed medication for the treatment of Attention Deficit hyperactivity Disorder (ADHD) on behavioural and brain imaging measures of cognition. Specifically, it measures the impact of Clonidine on key behaviours that are altered in ADHD including, response inhibition, attention and error processing.
Eligibility
Inclusion Criteria2
- healthy adult
- Normal or corrected to normal vision
Exclusion Criteria4
- History of psychiatric illness
- Currently on medication
- Smoker
- Regular recreational drug use
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A randomised placebo controlled trial of the effects of Clonidine (200mcg) on cognitive control and error processing measures in healthy adults. Clonidine trade name: Catapress Participants will receive each of Clonidine and placebo in capsule form (1 week apart, order of administration randomised). The Experimenter will observe ingestion of the capsule (time 0), participants will commence tasks after 90 minutes has elapsed (onset of drug peak), task will be completed at 180 minutes, observation will then occur for half an hour before completion at 210 minutes.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000093583